Amendments to the Claims

1. (Canceled)

2. (Canceled)

3. (Currently Amended) A method for preventing exaggerated restenosis in a diabetic subject at risk of developing exaggerated restenosis which comprises administering to the subject a therapeutically effective amount of a human or mouse soluble receptor for advanced glycation endproducts (sRAGE) so as to prevent exaggerated restenosis in the subject.

4. (Previously Presented) The method of claim 3, wherein the subject is a human.

5. (Previously Presented) The method of claim 3, wherein the subject has undergone an angioplasty procedure or has undergone surgery to implant a stent in a blood vessel.

6-10. (Canceled)

11. (Previously Presented) The method of claim 3, wherein the sRAGE is administered to the subject by bolus injection, intraperitoneal injection, i.v., oral administration, topical application to the blood vessel, coating of a device to be placed within the subject, coating of an instrument used during a procedure upon the subject which results in blood vessel injury, or contacting blood of the subject during extracorporeal circulation.

12. (Original) The method of claim 11, wherein the device to be placed within the subject is a stent or an angioplasty balloon.

13. (Previously Presented) The method of claim 3, wherein the sRAGE is administered to the subject at a rate from about 2 µg/kg/hr to about 100 µg/kg/hr.

14. (Previously Presented) The method of claim 3, wherein the sRAGE is coated onto a stent used during an angioplasty of the subject.

15-24. (Canceled)